Search

Displaying results 1351 - 1360 of 1640 in total
  1. Drug

    Zinc sulfate, unspecified form

    go.drugbank.com/drugs/DB14548
    Approved

    Zinc sulfate is a common zinc supplement in parenteral nutrition.

    Mixtures: Se-Tan PLUS
  2. Target

    Human Retinoid X Receptors (RXRs)

    go.drugbank.com/bio_entities/BE0010096
    TargetHumans

    Receptor for retinoic acid. … Receptor for retinoic acid.

    Polypeptides: Retinoic acid receptor RXR-alpha, Retinoic acid receptor RXR-betaSynonyms: Retinoid X receptor alpha, Retinoid X receptor beta
  3. Target

    Peroxisome proliferator-activated receptors

    go.drugbank.com/bio_entities/BE0010120
    TargetHumans and other mammals

    Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fatty acids. … Once activated by a ligand, the receptor binds to promoter elements of target genes. Regulates the peroxisomal beta-oxidation pathway of fatty acids.

    Polypeptides: Peroxisome proliferator-activated receptor alpha, Peroxisome proliferator-activated receptor deltaSynonyms: Nuclear hormone receptor 1, Nuclear receptor subfamily 1 group C member 1
  4. Drug

    Levomefolic acid

    go.drugbank.com/drugs/DB11256
    Approved

    Supplementation of levomefolic acid is desired over folic acid due to reduced potential for masking vitamin B12 deficiency symptoms.

  5. Drug

    Elacestrant

    go.drugbank.com/drugs/DB06374
    ApprovedInvestigational

    [A256828,A256863,L44948] Other types of endocrine therapy, such as selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs), may lead to drug resistance over time; therefore, the use … Elacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist.

    Categories: Estrogen Receptor Antagonists, Selective Estrogen Receptor Degraders
  6. Drug

    Quinidine

    go.drugbank.com/drugs/DB00908
    Approved

    [A38016] Due to its side effects and increased risk of mortality, the use of quinidine was reduced over the next few decades.

    Categories: Adrenergic alpha-1 Receptor Antagonists
  7. Drug

    Selpercatinib

    go.drugbank.com/drugs/DB15685
    ApprovedInvestigational

    Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.

  8. Drug

    RG2417

    go.drugbank.com/drugs/DB05055
    Investigational

    Recent reports indicate that certain genes that encode for mitochondrial proteins are significantly down regulated in the brains of bipolar patients.

  9. Drug

    DP-VPA

    go.drugbank.com/drugs/DB05821
    Investigational

    DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure frequency.

  10. Drug

    Fiboflapon

    go.drugbank.com/drugs/DB06346
    Investigational